{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:09:55Z","timestamp":1794978595615,"version":"4.9.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"JSPS KAKENHI","award":["24K11610"],"award-info":[{"award-number":["24K11610"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The efficacy of avacopan as remission induction therapy for Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (AAV) is well-established. However, concerns regarding liver injury post-avacopan treatment remain, especially in Japan. Therefore, this study aimed to investigate drug-induced liver injury (DILI) associated with avacopan treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study included 22 patients with AAV who were treated with avacopan at multiple centres in Japan between September 2021 and March 2024. DILI was assessed by the Japanese version of a revised electronic causality assessment method (RECAM-J 2023).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 22 patients treated with avacopan, DILI was observed in nine cases (40.9%): six with microscopic polyangiitis and three with granulomatosis with polyangiitis. Severe DILI with elevated total bilirubin (T-Bil) was observed in four of the nine patients (44.4%), a few weeks after the initiation of avacopan therapy. Eight of the nine patients (88.9%) with DILI improved after discontinuation of avacopan and other medications, and one patient developed vanishing bile duct syndrome (VBDS) leading to death. Avacopan-induced DILI was classified into three patterns: 1, short-term injury without T-Bil elevation; 2, transient cholestatic liver injury with T-Bil elevation; 3, decompensated liver injury with marked T-Bil elevation (VBDS). The risk factors for severe DILI with T-Bil elevation in Japanese patients included older age, lower body mass index and early onset DILI following the initiation of avacopan treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Avacopan-induced DILI is relatively common in Japan and could be lethal. Frequent laboratory follow-ups should be considered, especially for elderly and low-body-weight patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae689","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T03:01:54Z","timestamp":1734145314000},"page":"2533-2540","source":"Crossref","is-referenced-by-count":39,"title":["Drug-induced liver injury related to avacopan therapy"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0556-3513","authenticated-orcid":false,"given":"Kentaro","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-3494","authenticated-orcid":false,"given":"Tsuyoshi","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-8609","authenticated-orcid":false,"given":"Tomoyuki","family":"Mutoh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Osaki Citizen Hospital , Osaki, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine , Sendai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyoshi","family":"Fujishima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]},{"name":"Department of Pathology, Tohoku Medical and Pharmaceutical University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"2025050316130424000_keae689-B1","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update","volume":"10","author":"Almaani","year":"2021","journal-title":"J Clin Med"},{"key":"2025050316130424000_keae689-B2","doi-asserted-by":"crossref","first-page":"m421","DOI":"10.1136\/bmj.m421","article-title":"Management of ANCA associated vasculitis","volume":"368","author":"Wallace","year":"2020","journal-title":"BMJ"},{"key":"2025050316130424000_keae689-B3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2025050316130424000_keae689-B4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"2025050316130424000_keae689-B5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2025050316130424000_keae689-B6","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"2025050316130424000_keae689-B7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025050316130424000_keae689-B8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00011-010-0178-4","article-title":"C5a promotes migration, proliferation, and vessel formation in endothelial cells","volume":"59","author":"Kurihara","year":"2010","journal-title":"Inflamm Res"},{"key":"2025050316130424000_keae689-B9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025050316130424000_keae689-B10","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025050316130424000_keae689-B11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025050316130424000_keae689-B12","first-page":"1","article-title":"Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicenter real-world study","volume":"00","author":"Gabilan","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316130424000_keae689-B13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ekir.2022.01.1065","article-title":"Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option","volume":"7","author":"Gabilan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025050316130424000_keae689-B14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025050316130424000_keae689-B15","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3899\/jrheum.2024-0340","article-title":"Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"51","author":"Uchida","year":"2024","journal-title":"J Rheumatol"},{"key":"2025050316130424000_keae689-B16","article-title":"Efficacy and safety of avacopan over 12 months in japanese patients with MPA\/GPA: a single-center study [abstract]","volume":"76","author":"Ushio","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025050316130424000_keae689-B17","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316130424000_keae689-B18","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1093\/rheumatology\/kead561","article-title":"Comment on: a case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Shirota","year":"2024","journal-title":"Rheumatology (Oxford"},{"key":"2025050316130424000_keae689-B19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/mrcr\/rxad019","article-title":"Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Kataoka","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025050316130424000_keae689-B20","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s00467-024-06376-8","article-title":"A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis","volume":"39","author":"Nishino","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"2025050316130424000_keae689-B21","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan","volume":"63","author":"Kojima","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316130424000_keae689-B22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025050316130424000_keae689-B23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025050316130424000_keae689-B24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/hepr.14046","article-title":"RECAM-J 2023-validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury","volume":"54","author":"Tanaka","year":"2024","journal-title":"Hepatol Res"},{"key":"2025050316130424000_keae689-B25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"2025050316130424000_keae689-B26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/dmd.120.000261","article-title":"Functional characterization of 40 CYP3A4 variants by assessing Midazolam 1'-Hydroxylation and Testosterone 6beta-Hydroxylation","volume":"49","author":"Kumondai","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"2025050316130424000_keae689-B27","doi-asserted-by":"crossref","first-page":"102015","DOI":"10.1016\/j.clinre.2022.102015","article-title":"Vanishing bile duct syndrome after drug-induced liver injury","volume":"46","author":"Wasuwanich","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025050316130424000_keae689-B28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","article-title":"Criteria of drug-induced liver disorders: report of an International Consensus Meeting","volume":"11","author":"B\u00e9nichou","year":"1990","journal-title":"J Hepatol"},{"key":"2025050316130424000_keae689-B29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/hep.28967","article-title":"Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements","volume":"65","author":"Bonkovsky","year":"2017","journal-title":"Hepatology"},{"key":"2025050316130424000_keae689-B30","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316130424000_keae689-B31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3899\/jrheum.130602","article-title":"Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan","volume":"41","author":"Furuta","year":"2014","journal-title":"J Rheumatol"},{"key":"2025050316130424000_keae689-B32","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4550","article-title":"Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025050316130424000_keae689-B33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3899\/jrheum.160005","article-title":"Comparison of the phenotype and outcome of granulomatosis with polyangiitis between UK and Japanese cohorts","volume":"44","author":"Furuta","year":"2017","journal-title":"J Rheumatol"},{"key":"2025050316130424000_keae689-B34","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025050316130424000_keae689-B35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14397595.2016.1192760","article-title":"Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"27","author":"Murosaki","year":"2017","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae689\/61156965\/keae689.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2533\/61156965\/keae689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2533\/61156965\/keae689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:13:21Z","timestamp":1746303201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2533\/7923427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,13]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae689","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,13]]}}}